Cognition Clinical Trial
— ASHOfficial title:
A Randomized Study to Examine the Ability of a Caffeine-Based Energy Drink to Impact Energy Expenditure, Fat Oxidation, Reaction Time, and Other Perceptual Indicators
The purpose of this study is to evaluate the changes in energy expenditure, fat oxidation, reaction time, and perceptual indicators of energy and focus after acute ingestion of a caffeine-based energy drink. Approximately 60 healthy adults aged 18-50 will be recruited for a randomized, double-blind, placebo-controlled study. They will undergo baseline measurements for energy expenditure, fat and carbohydrate oxidation, reaction time, cognition, and perceptual indicators of energy, focus, and concentration. After 28 days, these measurements will be taken again, comparing the effects of a caffeine-based energy drink versus a placebo.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | March 1, 2024 |
Est. primary completion date | March 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria 1. Male or female participants between 18 - 50 years of age 2. Signed informed consent 3. Healthy, is defined as currently not being treated for an active cardiac, pulmonary, metabolic, immunological, neurological, respiratory, orthopedic, musculoskeletal, psychiatric, or reproductive disease or disorder. With the research team and principal investigator's discretion, some ongoing treatments will be permitted if a determination is made that the treatment will not increase the risk of study participation and the treatment will not confound with desired study outcomes 4. Physically active is defined as performing aerobic or resistance-based physical exercise between 2 and 5 times per week 5. Moderate caffeine users (~300 mg/day) 6. Body mass index values will range from >24.0 to < 31.9 kg/m2. The average body mass index for the entire study cohort will be less than 31.99 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 31.99 kg/m2 7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures Exclusion Criteria 1. Body mass index > 31.9 kg/m2 2. Positive medical history and/or is currently being treated for some form of heart or cardiovascular, neurological impairment, disease or condition, immune disorder or disease, thyroid disease, kidney disease, renal failure, regular dialysis, liver disease, or other diagnosed hepatic impairment 3. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL) 4. Diagnosed with a major affective disorder or other psychiatric disorder that required hospitalization in the prior year 5. History of cancer (except localized skin cancer without metastases or in situ 6. cervical cancer within 5 years prior to screening visit). 7. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) 7. Currently prescribed statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha-blockers, 8. Vasodilators, etc.) or any other medication at the discretion of the principal investigator 9. Current smoker (>10 cigarettes per day) 10. Participants who are lactating, pregnant, or planning to become pregnant History of alcohol or substance abuse in the 6 months prior to screening 11. Receipt or use of an investigational product in another research study within 60 days of beginning the study protocol 12. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data 13. Extensive travel (>1 month) that will disrupt the original outline of the study protocol |
Country | Name | City | State |
---|---|---|---|
United States | Exercise and Performance Nutrition Laboratory | Saint Charles | Missouri |
Lead Sponsor | Collaborator |
---|---|
Lindenwood University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Self-reported adverse events | Self-reported adverse events | 28 days | |
Other | Heart Rate | Resting heart rate | 28 days | |
Other | Blood Pressure | Resting Blood Pressure | 28 days | |
Primary | Energy expenditure (kcals/min) | Impact of a caffeine-based energy drink ingestion on energy expenditure (calorie burning) | 28 days | |
Secondary | Rates of fat oxidation | Impact of a caffeine-based energy drink ingestion on fat oxidation | 28 days | |
Secondary | Energy Visual Analog Scale | Impact of a caffeine-based energy drink ingestion on perceptual indicators of affect through visual analog scales (VAS) | 28 days | |
Secondary | Focus Visual Analog Scale | Impact of a caffeine-based energy drink ingestion on perceptual indicators of affect through visual analog scales (VAS) | 28 days | |
Secondary | Concentration Visual Analog Scale | Impact of a caffeine-based energy drink ingestion on perceptual indicators of affect through visual analog scales (VAS) | 28 days | |
Secondary | Simple reaction time | Impact of a caffeine-based energy drink ingestion on reaction time | 28 days | |
Secondary | Choice reaction time | Impact of a caffeine-based energy drink ingestion on reaction time | 28 days | |
Secondary | Trail Making Test | Impact of a caffeine-based energy drink ingestion on cognition | 28 days | |
Secondary | Serial Sevens | Impact of a caffeine-based energy drink ingestion on cognition | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04540523 -
Home-Based Exergaming Intervention
|
N/A | |
Suspended |
NCT01212029 -
Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging
|
N/A | |
Enrolling by invitation |
NCT05273970 -
Electrochemical and Electrophysiological Study
|
N/A | |
Recruiting |
NCT05227352 -
Bio-Experiential Spaces for Mental Health in Healthworkers
|
N/A | |
Completed |
NCT02671149 -
The Effect of Small Changes in Hydration on Cognition
|
N/A | |
Completed |
NCT01333306 -
Enhancing Cognitive Training Using tDCS
|
Phase 1 | |
Recruiting |
NCT05542199 -
Nutrition for Brain and Body Health (BB-Health) Feasibility Trial
|
N/A | |
Recruiting |
NCT06331286 -
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
|
N/A | |
Recruiting |
NCT06254638 -
Effectiveness of a Multicomponent Intervention to Promote Physical Activity Levels During the School Day (MOVESCHOOL)
|
N/A | |
Withdrawn |
NCT03224559 -
Applying Neuromodulation to Accelerate Training Effects
|
||
Completed |
NCT03129048 -
Mediterranean Diet, Weight Loss, and Cognition in Obese Older Adults
|
N/A | |
Recruiting |
NCT05394363 -
Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
|
||
Suspended |
NCT05107947 -
Light in Frail Elderly - the Effect of a Dynamic Light for Sleep and Circadian Rhythm
|
N/A | |
Recruiting |
NCT05372172 -
Tennessee Alzheimer's Project
|
||
Recruiting |
NCT05132517 -
Magnesium and Cognition After Stroke
|
||
Recruiting |
NCT05992571 -
Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity
|
N/A | |
Recruiting |
NCT06097182 -
Postbiotic Intervention for Acute Stress Management
|
N/A | |
Completed |
NCT01223404 -
Nicotinic Modulation of the Default Network
|
N/A | |
Completed |
NCT00687102 -
Cognition in the Study of Tamoxifen and Raloxifene
|
Phase 3 | |
Recruiting |
NCT04169230 -
Citalopram and Self Emotional Processing
|
N/A |